Catherine Burbage, MD
Hematology & Oncology · Georgetown, SCNPI 1639358310
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $649 and has fallen 61.3% since, to $251 in 2025. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 150 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$248
- Merck$246
- Bristol Myers Squibb$215
- Gilead$198
- AstraZeneca$173
- Amgen$145
- plus $2K from 35 others
Across 9 payments — averaging $1984.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$18K
What the payments were for
- Food & beverage$2,75199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $248 |
| Merck | 14 | $246 |
| Bristol Myers Squibb | 11 | $215 |
| Gilead | 8 | $198 |
| AstraZeneca | 9 | $173 |
| Amgen | 9 | $145 |
| Johnson & Johnson | 7 | $121 |
| Incyte Corporation | 6 | $118 |
| Pfizer | 6 | $111 |
| E.r. Squibb & Sons, L.L.C. | 7 | $102 |
| Sanofi | 4 | $86 |
| Genentech USA, Inc. | 4 | $75 |
| Daiichi Sankyo Inc. | 4 | $74 |
| Seagen Inc. | 4 | $71 |
| GSK | 3 | $70 |
| Coherus Oncology, Inc. | 4 | $62 |
| Eisai Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $48 |
| Bayer | 3 | $45 |
| Rigel Pharmaceuticals, Inc. | 3 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $42 |
| Array Biopharma Inc | 2 | $41 |
| Astellas Pharma US Inc | 2 | $39 |
| Tersera Therapeutics LLC | 2 | $37 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Stemline Therapeutics Inc. | 1 | $24 |
| G1 Therapeutics, Inc. | 1 | $22 |
| Immunomedics, Inc. | 1 | $21 |
| Myovant Sciences Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| Acrotech Biopharma Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Sobi, Inc | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
How this compares
$2,783 in reported general payments places this provider in the 40th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 119 | $1,728,709 |
| RevlimidLenalidomide | 62 | $985,552 |
| PomalystPomalidomide | 24 | $549,149 |
| CalquenceAcalabrutinib Maleate | 23 | $353,620 |
| PromactaEltrombopag Olamine | 14 | $267,714 |
| VenclextaVenetoclax | 29 | $188,171 |
| TagrissoOsimertinib Mesylate | 11 | $186,208 |
| EliquisApixaban | 79 | $79,448 |
| Abiraterone Acetate | 32 | $48,863 |
| XareltoRivaroxaban | 20 | $17,727 |
| Letrozole | 213 | $7,468 |
| Exemestane | 25 | $6,270 |
| Imatinib Mesylate | 37 | $3,034 |
| Hydroxyurea | 77 | $1,839 |
| Tamoxifen Citrate | 64 | $1,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $215 | $985,55262 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $102 | $549,14924 claims |
| AstraZenecaCalquence, Tagrisso | $173 | $539,82834 claims |
| NovartisPromacta | $248 | $267,71414 claims |
| AbbVieVenclexta | $16 | $188,17129 claims |
| PfizerEliquis | $111 | $79,44879 claims |
| Johnson & JohnsonXarelto | $121 | $17,72720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Georgetown
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
- Sashi NaiduRock Hill$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.